Business
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
SAN DIEGO--(BUSINESS WIRE)-- Today, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science
About this update from Maravai Lifesciences Holdings, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nToday, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514331075/en/Dr. Jerome Kim, Director General of IVI (left), standing next to TriLink’s Chief Commercial Officer, Becky Buzzeo, after signing the 'Memorandum of Understanding to Support the Development of mRNA-based Vaccines.'\nAccording to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives.\n\n\"This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),” said Maravai and TriLink’s Chief Commercial Officer, Becky Buzzeo. “By combining our expertise in nucleic acids with the International Vaccine Institute's global reach and commitment to public health, we are poised to profoundly impact global health equity. Together, we can accelerate the development and distribution of innovative mRNA vaccines, ensuring that more people, regardless of their geographic location, have access to the critical healthcare they need.\"\n\nSince its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe™ RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in San Diego, California.\n\nIVI, based in Seoul, Korea, is an autonomous international organization established in 1997 as an initiative of t...